Plus Therapeutics (PSTV) Equity Ratio (2010 - 2026)

Plus Therapeutics (PSTV) has 17 years of Equity Ratio data on file, last reported at 0.6 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.6, up 130.63% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.6 (up 130.63% YoY), and the FY2025 annual result was 0.24, up 118.14% from the prior year.
• Equity Ratio improved to 0.6 in Q1 2026 per PSTV's latest filing, from 0.24 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.6 in Q1 2026 and troughed at 1.96 in Q1 2025.
• A 5-year average of 0.11 and a median of 0.2 in 2023 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio plunged 1039.78% in 2024, then surged 143.1% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.27 in 2022, then sank by 143.83% to 0.12 in 2023, then tumbled by 1039.78% to 1.35 in 2024, then soared by 118.14% to 0.24 in 2025, then surged by 145.35% to 0.6 in 2026.
• Business Quant data shows PSTV's Equity Ratio at 0.6 in Q1 2026, 0.24 in Q4 2025, and 0.27 in Q3 2025.